Dosage forms

Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

Retrieved on: 
Wednesday, August 4, 2021
Dosage forms, Chemical engineering, Pharmaceutical industry, Tablet, Natural sciences, Applied sciences, Chemistry

Lexaria Biosciences proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing.

Key Points: 
  • Lexaria Biosciences proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing.
  • The companys technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules.
  • Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide.
  • By cutting through the overload of information in todays market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

Ground-breaking Technology by Micellae, a University of Toronto Spinout, Set to Revolutionize Cannabinoid Delivery

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Life sciences, Pharmacology, Dosage forms, Pharmaceutical industry, Excipient, Pharmacy, Drug delivery, Self-microemulsifying drug delivery system, Bioavailability

TORONTO, Aug. 4, 2021 /PRNewswire/ -Micellae Delivery Systems Inc. ("Micellae") today announced the launch of its breakthrough drug delivery technology, O2W, the fastest oral bioavailability-enhancing formulation.

Key Points: 
  • TORONTO, Aug. 4, 2021 /PRNewswire/ -Micellae Delivery Systems Inc. ("Micellae") today announced the launch of its breakthrough drug delivery technology, O2W, the fastest oral bioavailability-enhancing formulation.
  • University of Toronto (U of T) Researcher and Micellae's Founder and CEO, Dr. Mehdi Nouraei, highlighted that,"Emulsification technologies have previously been employed in cannabinoid-based products.
  • However, existing technologies are less than optimal and result in significant compromises, including slow onset of action, complex manufacturing, unpleasant taste, and short shelf-life.
  • O2W is the only self-dispersing and fully water-dilutable Self-Microemulsifying Drug Delivery System (SMEDDS) made with food-grade excipients.

Nobu Trading Plans U.S. Launch of its Innovative Health Products for Babies, Kids, and Adults

Retrieved on: 
Monday, August 2, 2021
Nose, Dosage forms, Nasal spray, Spray, Branches of biology, Life sciences

PALM BEACH, FL, Aug. 02, 2021 (GLOBE NEWSWIRE) -- This week, London-based Nobu Trading announced plans to export its popular healthcare product lines for babies, children, and adults to America.

Key Points: 
  • PALM BEACH, FL, Aug. 02, 2021 (GLOBE NEWSWIRE) -- This week, London-based Nobu Trading announced plans to export its popular healthcare product lines for babies, children, and adults to America.
  • We have cutting-edge healthcare products from Nobu Baby, Athomer and Dr. Kontos that will help babies, kids and adults with respiratory problems, said Norbert Bujtas, founder and CEO of Nobu Baby.
  • Bujtas said Incarvexx Essential Nasal Spray was developed by scientists and our nasal spray manufacturer to be the future of the nasal spray.
  • Bujtas said Nobu Trading will also introduce two nasal sprays from its Athomer product lines in September:
    Athomer Sea Water Nasal Spray with Propolis is a gentle, natural nasal spray for adults and children.

Rapid Therapeutic Announces Private Placement of $1.9 Million Convertible Notes

Retrieved on: 
Monday, August 2, 2021
Dosage forms

Maxim Group LLC is acting as the sole placement agent for the offering.

Key Points: 
  • Maxim Group LLC is acting as the sole placement agent for the offering.
  • RTSL has developed and is continuing to develop a series of complementary products in addition to its inhaler.
  • We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our other products.
  • RTSL makes no therapeutic claims regarding its products, the use of its products, or any results which can be obtained from using its products.

Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Retrieved on: 
Monday, August 2, 2021
Health sciences, Medicine, Clinical medicine, Zoonoses, Infectious diseases, Nose, Dosage forms, Pandemics, Virus, COVID-19, Nasal spray

It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.

Key Points: 
  • It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.
  • Available in the form of a simple nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.
  • SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORS) to treat and prevent microbial infections in 2017.
  • Available at https://www.clinicaltrialsarena.com/news/sanotize-nasal-spray-reduces-co...
    2 SaNOtize's "revolutionary" Covid-19 nasal spray bolstered by Phase II trial data.

Thompson Duke Industrial Releases Automated Vaporizer Filling Machine To Increase Process Efficiencies

Retrieved on: 
Thursday, July 29, 2021
Euphoriants, Psychoactive drugs, Entheogens, Medicinal plants, Cannabis smoking, Health sciences, Pharmacology, Dosage forms, Cannabis, Vaporizer, Hash oil

PORTLAND, Ore., July 29, 2021 /PRNewswire/ -- Thompson Duke Industrial , the leader in cannabis oil vaporizer device filling and capping equipment, has released its IZR Automatic Filling Machine .

Key Points: 
  • PORTLAND, Ore., July 29, 2021 /PRNewswire/ -- Thompson Duke Industrial , the leader in cannabis oil vaporizer device filling and capping equipment, has released its IZR Automatic Filling Machine .
  • "The IZR is a great example of Thompson Duke responding to the needs of the industry to solve a complex problem with a simple design," saidChris Gardella, Chief Technology Officer forThompson Duke Industrial.
  • Existing clients can readily upgrade their systems to IZR capabilities, as the machine works with all existing Thompson Duke Industrial ACF1 trays and components.
  • With over 1,200 filling machines deployed in the cannabis industry, Thompson Duke Industrial is the leader in cannabis oil vaporizer device filling and capping equipment.

Tunisia Pharmaceutical Market Size, Share & Trends Analysis 2021-2028 by Formulation (Tablets, Injectables, Sprays (BFS-mode, Non-BFS-mode), & Suspensions, Capsules, Powders) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Health, Pharmaceutical, Health sciences, Pharmaceutical sciences, Pharmacology, Pharmaceutical industry, Dosage forms, Pharmacy, Tablet, Capsule, Pharmaceutics

The "Tunisia Pharmaceutical Market Size, Share & Trends Analysis Report by Formulation (Tablets, Injectables, Sprays (BFS-mode, Non-BFS-mode), Suspensions, Capsules, Powders) and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tunisia Pharmaceutical Market Size, Share & Trends Analysis Report by Formulation (Tablets, Injectables, Sprays (BFS-mode, Non-BFS-mode), Suspensions, Capsules, Powders) and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Tunisia pharmaceutical market size is estimated to reach USD 3.4 billion by 2028.
  • The market is expected to expand at a CAGR of 12.9% from 2021 to 2028.
  • The market is largely driven by the improving pharmaceutical exports of Tunisia, which is a result of expanding pool of local pharmaceutical manufacturers in the country.

Shatterizer inc. launches their newest edition to the family, the BUBBLER by Shatterizer

Retrieved on: 
Wednesday, July 28, 2021
Cannabis smoking, Psychoactive drugs, Health sciences, Pharmacology, Euphoriants, Drug paraphernalia, Dosage forms, Cannabis, Vaporizer, Bubbler

Toronto, ON, July 28, 2021 (GLOBE NEWSWIRE) -- Shatterizer inc. is pleased to announce their revolutionary portable and desktop cannabis extracts vaporizer, the BUBBLER by Shatterizer .

Key Points: 
  • Toronto, ON, July 28, 2021 (GLOBE NEWSWIRE) -- Shatterizer inc. is pleased to announce their revolutionary portable and desktop cannabis extracts vaporizer, the BUBBLER by Shatterizer .
  • In 2021, Shatterizer aims to surpass expectations with their newest product, the BUBBLER by Shatterizer .
  • The BUBBLER by Shatterizer is the most innovative cannabis concentrate vaporizer to hit the market.
  • We believe in delivering market disrupting products, and we personally love the BUBBLER by Shatterizer, expect even more #PerfectClouds in 2021!

$2.3 Billion Worldwide Digital Dose Inhalers Industry to 2027 - Impact Analysis of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Medical devices, Health, Technology, Infectious diseases, Other Technology, Managed care, Dosage forms, Health sciences, Health care, Asthma, Respiratory therapy, Health, Inhaler

The "Digital Dose Inhalers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Digital Dose Inhalers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Digital Dose Inhalers estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$5.5 Billion by 2027, growing at a CAGR of 13.1% over the period 2020-2027.
  • Metered Dose, one of the segments analyzed in the report, is projected to grow at a 12.4% CAGR to reach US$3.4 Billion by the end of the analysis period.
  • This segment currently accounts for a 35.7% share of the global Digital Dose Inhalers market.

OnMi Transdermal Patches Give You Everything You Want and Nothing You Don’t

Retrieved on: 
Thursday, July 22, 2021
Health sciences, Pharmacology, Health, Routes of administration, Dosage forms, Transdermal patch, Gluten-free diet, Topical medication, Paraben, Tablet, Transdermal, Gluten

We developed transdermal patches that deliver naturally derivedvitamins and botanicals, said Ryan McFarlane, COO of OnMi.

Key Points: 
  • We developed transdermal patches that deliver naturally derivedvitamins and botanicals, said Ryan McFarlane, COO of OnMi.
  • Our transdermal patches allow ingredients to be absorbed topically without the filler ingredients that many pills and tabletscontain.
  • McFarlane said consumers might not realize that pills and tablets contain ingredients used as a lubricant for the machines that make them.
  • OnMi products, which only contain plant-based ingredients and vitamins, are also Non-GMO, Paraben Free, Dye Free, Gluten Free, and Latex Free.